SEC Form 4 · accession 0001651844-16-000011

NYMOX PHARMACEUTICAL CORP · NYMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 4, 2016

Accepted (ET)

Jan 8, 2016 · 5:20 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001018735

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 4, 2016	P	5,000	$3.11	A	2,547,550	D
Common Stock	Jan 4, 2016	P	3,583	$3.07	A	2,551,133	D
Common Stock	Jan 5, 2016	P	6,417	$3.07	A	2,557,550	D
Common Stock	Jan 5, 2016	P	10,000	$3.21	A	2,567,550	D
Common Stock	Jan 6, 2016	P	9,350	$3.08	A	2,576,900	D
Common Stock	Jan 7, 2016	P	10,000	$2.99	A	2,586,900	D
Common Stock	Jan 7, 2016	P	10,000	$2.91	A	2,596,900	D
Common Stock	Jan 7, 2016	P	10,650	$2.84	A	2,607,550	D
Common Stock	Jan 8, 2016	P	10,000	$2.60	A	2,617,550	D
Common Stock	Jan 8, 2016	P	10,000	$2.57	A	2,627,550	D
Common Stock	Jan 8, 2016	P	10,000	$2.71	A	2,637,550	D
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust

No Table II lines on this filing.